IRIS
FANIN, Renato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.117
EU - Europa 5.735
AS - Asia 2.089
AF - Africa 32
SA - Sud America 28
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 3
Totale 30.022
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.987
UA - Ucraina 2.095
CN - Cina 950
DE - Germania 884
SG - Singapore 724
IT - Italia 690
FI - Finlandia 641
SE - Svezia 473
IE - Irlanda 367
RU - Federazione Russa 254
TR - Turchia 168
CA - Canada 126
GB - Regno Unito 110
FR - Francia 89
VN - Vietnam 85
IN - India 60
IR - Iran 41
BE - Belgio 24
CZ - Repubblica Ceca 24
BR - Brasile 22
EU - Europa 18
TG - Togo 18
HK - Hong Kong 17
NL - Olanda 17
KR - Corea 14
JP - Giappone 11
PL - Polonia 11
RO - Romania 10
EG - Egitto 8
CH - Svizzera 7
ES - Italia 7
ID - Indonesia 7
RS - Serbia 7
AT - Austria 6
ZA - Sudafrica 6
BG - Bulgaria 5
IL - Israele 4
AR - Argentina 3
AU - Australia 3
LU - Lussemburgo 3
MX - Messico 3
GR - Grecia 2
HU - Ungheria 2
LT - Lituania 2
LV - Lettonia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CO - Colombia 1
EC - Ecuador 1
GL - Groenlandia 1
KH - Cambogia 1
KZ - Kazakistan 1
LI - Liechtenstein 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 30.022
Salva come PNG Salva come JPEG
Città #
Fairfield 2.992
Woodbridge 2.894
Houston 1.964
Ann Arbor 1.893
Jacksonville 1.415
Ashburn 1.292
Seattle 1.216
Wilmington 1.128
Chandler 1.108
Cambridge 980
Dearborn 890
Singapore 598
Boardman 485
Beijing 423
Princeton 382
Dublin 367
Udine 276
San Diego 188
Izmir 168
Ogden 99
Ottawa 97
Norwalk 86
Dong Ket 84
Des Moines 75
Hefei 62
Nanjing 55
Redmond 50
Trieste 47
Santa Clara 43
Kunming 41
New York 41
Dallas 38
Milan 34
Guangzhou 32
Los Angeles 31
Regensburg 29
Simi Valley 29
Helsinki 25
Brussels 24
Jinan 23
Nanchang 23
Hangzhou 21
Saint Petersburg 21
Leawood 20
Toronto 20
Munich 19
Grafing 18
Lomé 18
Hong Kong 17
Shenyang 17
Phoenix 15
Venezia 15
Fuzhou 14
Wuhan 14
Andover 13
Chengdu 13
Falls Church 13
Shanghai 13
Augusta 12
San Mateo 12
Washington 12
Zanjan 12
Brno 11
Frankfurt am Main 11
Monmouth Junction 11
Rome 11
Ardabil 10
Warsaw 10
Zhengzhou 10
Chongqing 9
Duino-Aurisina 9
Hyderabad 9
London 9
Indiana 8
Belgrade 7
Cairo 7
Hebei 7
Redwood City 7
Tokyo 7
Amsterdam 6
Jiaxing 6
Lappeenranta 6
Modderfontein 6
Montreal 6
Mumbai 6
Olomouc 6
Prague 6
Zurich 6
Changsha 5
Edinburgh 5
Horia 5
Murano 5
Ningbo 5
Pune 5
Spinea 5
São Paulo 5
Buffalo 4
Chaoyang 4
Florence 4
Henderson 4
Totale 22.319
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 236
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 205
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 181
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 155
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 151
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 147
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 146
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 143
Atypical haemolytic-uraemic syndrome at the onset of acute promyelocytic leukaemia. 142
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 141
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 139
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 137
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 137
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 135
Multipotent Progenitor Cells Are Present in Human Peripheral Blood. 135
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 134
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 134
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 134
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 132
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 132
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 131
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 130
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 129
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 128
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells 128
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 127
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 125
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 124
Management of immune thrombocytopenia in elderly patients 124
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. 123
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 123
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 123
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 123
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 122
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 122
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 122
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 122
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 121
“Overexpression of multidrug resistance-associated P-170 glycoprotein in acute non lymphocytic leukemia”. 120
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. 119
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 119
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 118
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 118
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 118
Autologous stem cell transplantation in chronic carriers of hepatitis B virus and hepatitis C virus affected by onco-hematologic diseases. 118
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 117
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 116
Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome. 115
Family history of cancer and risk of second malignancies in young cancer patients in Trieste, Italy. 115
Granulocyte-macrophage colony -stimulating factor in acute nonlymphocytic leukemia before and after chemo therapy”. 115
Pre-Chemotherapy risk factors for invasive fungal diseases: Prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (seifem 2010-a multicenter study) 115
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 115
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 114
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 113
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 113
WHO classification and WPSS predict post-transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 112
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 112
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 112
P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. 111
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 111
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias 111
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 111
Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). 110
Wilms' tumor 1 gene expression levels in acute promyelocytic leukemia compared to other acute myeloid leukemia subtypes 110
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 110
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 109
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study 109
A comparison of allografting with autografting for newly diagnosed myeloma 108
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 108
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 108
Rituximab for the treatment of type II mixed cryoglobulinemia. 107
Unexpected phenotype of a typical NPM1 mutant 107
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 107
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 107
Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT 107
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 106
“Case report: mdr-1 gene amplification in acute lymphoblastic leukemia prior to antileukemic treatment”. 106
Multipotent Mesenchymal Stem Cells Can Be Isolated and Grown from Many Tissues (Bone Marrow, Liver and Heart) 106
Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. 105
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation 105
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 105
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 105
Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Tr antibodies in a patient with Hodgkin's disease 104
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. 104
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 104
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 104
The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. 104
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 104
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 104
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 104
“CD34+ selected versus un-manipulated autologous stem cell transplantation in multiple myeoloma: impact on dendritic and immune recovery and on complications due to infections”. 103
Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. 103
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 103
Leukaemic infiltration of the retina at onset of Philadelphia-positive acute lymphoblastic leukaemia revealed by stratus optical coherence tomography 103
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 102
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. 102
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 102
Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. 102
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 102
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 102
Totale 12.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.177
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.177
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.074 0 0 0 0 0 0 960 1.012 628 682 190 602
2020/20214.950 134 598 144 577 207 617 356 600 644 183 596 294
2021/20223.100 117 364 156 225 93 144 185 143 56 507 634 476
2022/20232.817 419 159 31 328 259 829 14 207 384 37 86 64
2023/2024853 122 66 27 27 132 100 17 53 142 65 32 70
2024/20251.808 149 502 381 170 292 309 5 0 0 0 0 0
Totale 31.038